Pharma's Almanac TV
PA TV
Your Name
Your Email
Manage Account
Sign Out
Sign In
Register
Follow the Journey
Companies On The Road
Arcadis DPS Group
C2 Pharma
CAI
EcoLab
Environmental Systems Corporation
Federal Equipment Company
Globyz Biopharma Services
Grifols
Integrity
Nu-Tek BioSciences
PHARMALEX
Waters Corporation
Follow the Journey
Companies On The Road
ABS
aCGT Vector
Alconox Inc.
Andelyn Biosciences
Arranta Bio
Avid Bioservices
BDD
BIOVECTRA
DPS Group
Dynamk Capital
Environmental Systems Corporation
Federal Equipment Company
Genesis AEC
Globyz Biopharma Services
Grifols Partnership
IDT Biologika
Inceptor Bio
IPS-Integrated Project Services
Kineticos Life Sciences
MilliporeSigma
Montana BioScience Alliance
Olon
Rentschler Biopharma
SanaClis
Scorpion Biological Services
Secant Group
Tapemark
VITRONIC
Follow the Journey
Companies On The Road
AES Clean Technology
Altis Biosystems
Arranta Bio
Avara Pharmaceutical Services
Avid Bioservices
BioVectra
Centaur BPS
Dynamk Capital
ECRI
Evolve Biologics
Federal Equipment Company
Globyz
Inceptor Bio
IPS-Integrated Project Services
Olon
Pii
Polpharma Biologics
PPD
RoosterBio
SanaClis
Sanofi AIS
SGD Pharma
SPI Pharma
TriRx Pharmaceutical Services
Yourway
Dashboard
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Magazine
Archive
Reports
Nice Insight Reports
2022 Sterile
2023 Cell & Gene Therapy
2023 mAb and Recombinant Protein
2024 API
2024 OSD
2024 ADC
2024 mRNA
2024 Mammalian Cell Culture
2024 Microbial Cell Culture
2024 Plasmids
2024 Gene Therapy
2024 Cell Therapy
2024 Sterile
Community
Company A to Z
Follow the Journey
Companies On The Road
Follow The Artist
Follow the Journey
Companies On The Road
More+
Staffing
Media Kit
Diabetes
47 Articles Available
0
2
Can't find what you're looking for? Try our
advanced search
.
Column: New Drug Watch
New Drug Watch: A Validation of the ‘Twincretin’ Approach to Type 2 Diabetes
PAO-06-022--NI-08
Diabetes Research
Composition of Gut Microbiome Predicts the Onset of Type 2 Diabetes
PR-M02-22-13
Digital Therapeutics
Digital Therapeutics: Redefining Prescription Medication in the Information Era
PAO-05-21-NI-01
New $35 Co-Pay Now Available Through Lilly Insulin Value Program in Response to COVID-19 Crisis in U.S.
PR-M04-20-NI-010
Insulin Delivery
Abbott and Insulet Partner to Integrate Next-Generation Glucose Sensing and Automated Insulin Delivery Technologies for Seamless Diabetes Care
PR-M02-20-NI-043
Update
KalVista Pharmaceuticals Provides Update on Diabetic Macular Edema Programs
PR-M02-20-NI-011
Drug Pricing
Lilly Expands Insulin Affordability Options
PR-M01-20-NI-028
Diabetes
Sanofi to Exit Diabetes and Cardiovascular Research
PAO-M12-19-NI-005
Drug Approval
Qtrilmet Approved in the EU for the Treatment of Type-2 Diabetes
PR-M11-19-NI-020
Diabetes Prevention
Sigrid Therapeutics Takes Another Step Towards a Treatment for Prevention of Type 2 Diabetes
PR-M10-19-NI-032
Approval
Farxiga Approved in the US to Reduce the Risk of Hospitalization for Heart Failure in Patients with Type-2 Diabetes
PR-M10-19-NI-029
Drug Delivery
New Capsule Can Orally Deliver Drugs that Usually Have to be Injected
PR-M10-19-NI-022
Drug Pricing
Novo Nordisk Launching Additional US Insulin Affordability Offerings in January 2020
M&A
Vertex to Acquire Semma Therapeutics With a Goal of Developing Curative Cell-Based Treatments for Type 1 Diabetes
PR-M09-19-NI-008
Heathcare
Blue Cross and Blue Shield of Minnesota to Cover Insulin Costs at No Charge Next Year
PR-M08-19-NI-081
Licensing Agreement
Innovent Enters a Licensing Agreement with Lilly to Develop & Commercialize a Novel Diabetes Medicine in China
PR-M08-19-NI-076
FDA Approval
Aptar’s Nasal Unidose Device Approved by US FDA for First Needle-Free Rescue Treatment for Severe Hypoglycemia
PR-M08-19-NI-025
Diabetes
Forxiga Label Updated in the EU in Type-2 Diabetes
PR-M08-19-NI-017
FDA
FDA Says No to Farxiga for Type 1 Diabetes
PAO-M08-19-NI-002
Diabetes
Preclinical Studies Bode Well for Diabetes Drug from Semma Therapeutics
PAO-M07-19-NI-009
FDA
FDA Warns Patients and Healthcare Providers About Potential Cybersecurity Concerns with Certain Medtronic Insulin Pumps
PR-M07-19-NI-012
Series B Financing
DayTwo Secures $31 Million In Series B Financing To Scale Microbiome Research Platform To Address Chronic Health Conditions
PR-M06-19-NI-059
Diabetes
Common Glycemic Control Drug Could Have Other Significant Positive Effects for Type 2 Diabetes Patients
PAO-M06-19-NI-012
Cell and Gene Therapy
Semma Therapeutics Announces Publication in Nature Demonstrating Advancements in Regenerative Cell Therapy for Type 1 Diabetes
PR-M05-19-NI-039
«
0
2
»
.svg)